CN114982873A - 一种高效构建小鼠肥胖模型的高脂饲料及造模方法 - Google Patents
一种高效构建小鼠肥胖模型的高脂饲料及造模方法 Download PDFInfo
- Publication number
- CN114982873A CN114982873A CN202210363207.XA CN202210363207A CN114982873A CN 114982873 A CN114982873 A CN 114982873A CN 202210363207 A CN202210363207 A CN 202210363207A CN 114982873 A CN114982873 A CN 114982873A
- Authority
- CN
- China
- Prior art keywords
- group
- fat
- feed
- week
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000008589 Obesity Diseases 0.000 title claims abstract description 52
- 235000020824 obesity Nutrition 0.000 title claims abstract description 52
- 238000000034 method Methods 0.000 title claims abstract description 30
- 241000699670 Mus sp. Species 0.000 claims abstract description 56
- 241000699666 Mus <mouse, genus> Species 0.000 claims abstract description 47
- 229940088594 vitamin Drugs 0.000 claims abstract description 20
- 229930003231 vitamin Natural products 0.000 claims abstract description 20
- 235000013343 vitamin Nutrition 0.000 claims abstract description 20
- 239000011782 vitamin Substances 0.000 claims abstract description 20
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 17
- 239000008103 glucose Substances 0.000 claims abstract description 17
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 14
- 239000011707 mineral Substances 0.000 claims abstract description 14
- 244000269722 Thea sinensis Species 0.000 claims abstract description 13
- 235000013336 milk Nutrition 0.000 claims abstract description 13
- 239000008267 milk Substances 0.000 claims abstract description 13
- 210000004080 milk Anatomy 0.000 claims abstract description 13
- 239000000843 powder Substances 0.000 claims abstract description 13
- 239000001913 cellulose Substances 0.000 claims abstract description 12
- 229920002678 cellulose Polymers 0.000 claims abstract description 12
- 235000013310 margarine Nutrition 0.000 claims abstract description 12
- 239000003264 margarine Substances 0.000 claims abstract description 12
- 235000010980 cellulose Nutrition 0.000 claims abstract description 11
- 235000019483 Peanut oil Nutrition 0.000 claims abstract description 10
- 239000005018 casein Substances 0.000 claims abstract description 10
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims abstract description 10
- 235000021240 caseins Nutrition 0.000 claims abstract description 10
- 239000000312 peanut oil Substances 0.000 claims abstract description 10
- 235000011803 sesame oil Nutrition 0.000 claims abstract description 10
- 239000008159 sesame oil Substances 0.000 claims abstract description 10
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims abstract description 9
- 239000004158 L-cystine Substances 0.000 claims abstract description 9
- 235000019393 L-cystine Nutrition 0.000 claims abstract description 9
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 9
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 9
- 229960004874 choline bitartrate Drugs 0.000 claims abstract description 9
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 claims abstract description 9
- 229960003067 cystine Drugs 0.000 claims abstract description 9
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 9
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 4
- 229960001031 glucose Drugs 0.000 claims abstract description 4
- 235000010755 mineral Nutrition 0.000 claims description 13
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 12
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 10
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 8
- 229920002261 Corn starch Polymers 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 239000008120 corn starch Substances 0.000 claims description 8
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 6
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 6
- 229960002685 biotin Drugs 0.000 claims description 6
- 235000020958 biotin Nutrition 0.000 claims description 6
- 239000011616 biotin Substances 0.000 claims description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 6
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 claims description 6
- 235000009200 high fat diet Nutrition 0.000 claims description 5
- 229940042585 tocopherol acetate Drugs 0.000 claims description 5
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 4
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 4
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 4
- 229960002413 ferric citrate Drugs 0.000 claims description 4
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 claims description 4
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 claims description 4
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 claims description 4
- RETNOKWGJNESQA-UHFFFAOYSA-L manganese(2+);carbonate;hydrate Chemical compound O.[Mn+2].[O-]C([O-])=O RETNOKWGJNESQA-UHFFFAOYSA-L 0.000 claims description 4
- PJAHUDTUZRZBKM-UHFFFAOYSA-K potassium citrate monohydrate Chemical compound O.[K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PJAHUDTUZRZBKM-UHFFFAOYSA-K 0.000 claims description 4
- 229940050931 potassium citrate monohydrate Drugs 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 3
- 235000006481 Colocasia esculenta Nutrition 0.000 claims description 3
- 244000205754 Colocasia esculenta Species 0.000 claims description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 3
- 229930003779 Vitamin B12 Natural products 0.000 claims description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 3
- 229930003448 Vitamin K Natural products 0.000 claims description 3
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 claims description 3
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 3
- 229960002079 calcium pantothenate Drugs 0.000 claims description 3
- OIDPCXKPHYRNKH-UHFFFAOYSA-J chrome alum Chemical compound [K]OS(=O)(=O)O[Cr]1OS(=O)(=O)O1 OIDPCXKPHYRNKH-UHFFFAOYSA-J 0.000 claims description 3
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 3
- 229940116318 copper carbonate Drugs 0.000 claims description 3
- GEZOTWYUIKXWOA-UHFFFAOYSA-L copper;carbonate Chemical compound [Cu+2].[O-]C([O-])=O GEZOTWYUIKXWOA-UHFFFAOYSA-L 0.000 claims description 3
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims description 3
- 229960000304 folic acid Drugs 0.000 claims description 3
- 235000019152 folic acid Nutrition 0.000 claims description 3
- 239000011724 folic acid Substances 0.000 claims description 3
- 229960002715 nicotine Drugs 0.000 claims description 3
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 3
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 3
- JLKDVMWYMMLWTI-UHFFFAOYSA-M potassium iodate Chemical compound [K+].[O-]I(=O)=O JLKDVMWYMMLWTI-UHFFFAOYSA-M 0.000 claims description 3
- 239000001230 potassium iodate Substances 0.000 claims description 3
- 235000006666 potassium iodate Nutrition 0.000 claims description 3
- 229940093930 potassium iodate Drugs 0.000 claims description 3
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 3
- 229960002477 riboflavin Drugs 0.000 claims description 3
- 235000019192 riboflavin Nutrition 0.000 claims description 3
- 239000002151 riboflavin Substances 0.000 claims description 3
- 239000011775 sodium fluoride Substances 0.000 claims description 3
- 235000013024 sodium fluoride Nutrition 0.000 claims description 3
- 239000011781 sodium selenite Substances 0.000 claims description 3
- 235000015921 sodium selenite Nutrition 0.000 claims description 3
- 229960001471 sodium selenite Drugs 0.000 claims description 3
- 229960000344 thiamine hydrochloride Drugs 0.000 claims description 3
- 235000019190 thiamine hydrochloride Nutrition 0.000 claims description 3
- 239000011747 thiamine hydrochloride Substances 0.000 claims description 3
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 3
- 235000019163 vitamin B12 Nutrition 0.000 claims description 3
- 239000011715 vitamin B12 Substances 0.000 claims description 3
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 3
- 235000005282 vitamin D3 Nutrition 0.000 claims description 3
- 239000011647 vitamin D3 Substances 0.000 claims description 3
- 235000019168 vitamin K Nutrition 0.000 claims description 3
- 239000011712 vitamin K Substances 0.000 claims description 3
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 3
- -1 vitamin acetate Chemical class 0.000 claims description 3
- 229940021056 vitamin d3 Drugs 0.000 claims description 3
- 229940046010 vitamin k Drugs 0.000 claims description 3
- 239000011667 zinc carbonate Substances 0.000 claims description 3
- 235000004416 zinc carbonate Nutrition 0.000 claims description 3
- 229910000010 zinc carbonate Inorganic materials 0.000 claims description 3
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000019634 flavors Nutrition 0.000 claims description 2
- 235000005911 diet Nutrition 0.000 claims 1
- 230000037213 diet Effects 0.000 claims 1
- 238000010172 mouse model Methods 0.000 claims 1
- 235000019197 fats Nutrition 0.000 abstract description 31
- 238000000465 moulding Methods 0.000 abstract description 22
- 201000004384 Alopecia Diseases 0.000 abstract description 13
- 235000019629 palatability Nutrition 0.000 abstract description 9
- 231100000360 alopecia Toxicity 0.000 abstract description 8
- 150000002632 lipids Chemical class 0.000 abstract description 5
- 238000009825 accumulation Methods 0.000 abstract description 4
- 150000004670 unsaturated fatty acids Chemical class 0.000 abstract description 4
- 235000021122 unsaturated fatty acids Nutrition 0.000 abstract description 4
- 230000028327 secretion Effects 0.000 abstract description 3
- 210000004369 blood Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 20
- 230000000694 effects Effects 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 10
- 102000011632 Caseins Human genes 0.000 description 7
- 108010076119 Caseins Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 210000000028 corpus adiposum pararenale Anatomy 0.000 description 6
- 201000010063 epididymitis Diseases 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 230000006996 mental state Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000003676 hair loss Effects 0.000 description 5
- 208000024963 hair loss Diseases 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 235000019786 weight gain Nutrition 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 210000000579 abdominal fat Anatomy 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 230000009194 climbing Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000003808 decrease of hair loss Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000001596 intra-abdominal fat Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229940067631 phospholipid Drugs 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 210000004003 subcutaneous fat Anatomy 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 206010006956 Calcium deficiency Diseases 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 238000008789 Direct Bilirubin Methods 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- 208000008167 Magnesium Deficiency Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 235000019541 flavored milk drink Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 235000004764 magnesium deficiency Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000011623 obesity animal model Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000018405 transmission of nerve impulse Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/50—Feeding-stuffs specially adapted for particular animals for rodents
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/02—Breeding vertebrates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/20—Animal feeding-stuffs from material of animal origin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/105—Aliphatic or alicyclic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/174—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/26—Compounds containing phosphorus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/30—Oligoelements
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
- Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
- Y02P60/87—Re-use of by-products of food processing for fodder production
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Environmental Sciences (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Physiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Birds (AREA)
- Fodder In General (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供的一种高效构建小鼠肥胖模型的高脂饲料包括酪蛋白、L‑胱氨酸、纤维素、混合矿物质、混合维生素、酒石酸氢胆碱、葡萄糖、麦芽糊精、花生油、芝麻油、人造黄油、奶茶粉末。该高脂饲料的造模方法步骤如下,小鼠第1周和第3周分别投喂所述的高脂饲料,第2周和第4周分别投喂普通生长繁殖饲料,第5周至第n周一直投喂该高脂饲料直至小鼠肥胖模型成模。该高脂饲料适口性较高,有助于能量过多堆积引起肥胖的发生,饲料中的不饱和脂肪酸能够改善小鼠肥胖模型的皮肤脂质分泌过量造成的脂溢性脱毛。应用间隔喂养的方法能够大大缩短建模时间,成模率高且成模时间统一。
Description
技术领域
本发明属于生物技术领域,具体涉及一种高效构建小鼠肥胖模型的高脂饲料及造模方法。
背景技术
人类肥胖的原因多系能量摄入过多致体内脂肪堆积。为给肥胖疾病的治疗制定科学的诊断方案,人类疾病动物模型常应用于前期的理论研究,研究多采用高脂饲料诱导建立肥胖动物模型。目前常见的诱导肥胖模型常选择SD大鼠、Wistar大鼠、C57BL/6J小鼠。但目前国内外生物公司生产的高脂饲料在成模率和造模时间方面差强人意。使用传统高脂饲料配方(以:猪油+基础饲料为主)构建大鼠肥胖模型其造模时间需要在8-10周,C57BL/6J小鼠则需要10-12周,实验周期长,且造模鼠成模率很难达到80%,具造模时间长、成模率不高和适口性低的特点,在外观方面长期饲喂高脂饲料会导致小鼠皮肤脂分泌过旺而形成脂溢性脱毛等问题。目前实验室多采用单一高脂饲料喂养的造模方法用于构建动物肥胖模型,由于高脂饲料本身适口性低,并且连续单一喂养,容易致使动物产生厌食等问题导致食物利用率低、体重增长不稳定等问题。
发明内容
针对现有技术存在的问题,本发明提供一种高效构建小鼠肥胖模型的高脂饲料及造模方法,具体方案如下:
一种高效构建小鼠肥胖模型的高脂饲料,所述高脂饲料为60%脂供能高脂饲料,它包括酪蛋白、L-胱氨酸、纤维素、混合矿物质、混合维生素、酒石酸氢胆碱、葡萄糖、麦芽糊精、花生油、芝麻油、人造黄油、奶茶粉末。
进一步地,所述高脂饲料由以下重量百分比的组分组成:23%酪蛋白、0.39%L-胱氨酸、6.46%纤维素、6.46%混合矿物质、0.13%混合维生素、0.26%酒石酸氢胆碱、11%葡萄糖、14.15%麦芽糊精、2.53%花生油、2.53%芝麻油、28%人造黄油、5.09%奶茶粉末。
进一步地,所述奶茶粉末为香芋口味。
进一步地,所述混合矿物质由以下重量百分比的组分组成:17.985%玉米淀粉、33%一水柠檬酸钾、26%磷酸氢钙、11%碳酸钙、5.18%氯化钠、5.152%七水硫酸镁、0.838%重质氧化镁、0.42%柠檬酸铁、0.245%碳酸锰水合物、0.112%碳酸锌、0.039%硫酸铬钾、0.021%碳酸铜、0.006%氟化钠、0.001%***钠、0.001%碘酸钾。
进一步地,所述混合维生素由以下重量百分比的组分组成:78.42%玉米淀粉、10%生育酚乙酸酯、3%烟碱、2%生物素、1.6%泛酸钙、1%维生素D3(10万IU/g)、1%维生素B12、0.8%维生素醋酸酯(50万IU/g)、0.7%维生素B6盐酸盐、0.6%核黄素、0.6%硫胺素盐酸盐、0.2%叶酸、0.08%水溶性维生素K。
进一步地,所述生育酚乙酸酯的纯度50%,所述生物素的纯度为1%。
如所述的一种高效构建小鼠肥胖模型的高脂饲料在构建小鼠肥胖模型的应用。
一种小鼠肥胖模型的构建方法,包括如下步骤:小鼠第1周和第3周分别投喂所述的高脂饲料,第2周和第4周分别投喂普通生长繁殖饲料,第5周至第n周一直投喂所述的高脂饲料直至小鼠肥胖模型成模。
酪蛋白:酪蛋白是一种含磷钙结合蛋白,属于一种蛋白质成分。具有调节血脂功能的作用。能补充体内所需的钙元素,缓解缺钙所引发的肌肉酸软、抽筋现象,同时对于骨质疏松、生长发育迟缓等症也能起到缓解作用,还能预防缺铁性贫血和缺镁性神经炎。
L-胱氨酸:作饲料营养强化剂,有利于动物发育,增加体重和肝肾机能,提高毛皮质量。
纤维素:促进肠胃蠕动,保持肠道通畅,保持正常进食量。
混合矿物质型号为S10026B:提供动物正常生长发育所需的矿物元素。
混合维生素型号为V10001C:提供动物正常生长发育所需的维生素。
酒石酸氢胆碱:以磷酸酯或乙酰胆碱的形式广泛分布体内,与磷脂的代谢、神经冲动的传递以及阻止异常量的脂肪在肝脏中累计有关。
葡萄糖:参与新陈代谢,能被机体直接吸收转化并供能,
麦芽糊精:具有增稠作用能对饲料的塑性,保持饲料的硬度及形状。含有一定量的维生素和微量元素、促进机体正常的物质代谢和新陈代谢。
花生油:含有丰富的不饱和脂肪酸,增强脂质代谢、预防心脑血管疾病、抗氧化抗衰老的作用。能改善小鼠机体因食用过多高脂高热量饲料造成的负面效果。
芝麻油:含有丰富的不饱和脂肪酸,且有很好的润滑肠道、促进排便、缓解和治疗便秘的作用。最重要的是能抑制脱发,改善因长期食用高脂饲料而造成的脂溢性脱发问题。
人造黄油:属于反式脂肪酸食物,具有芳香气味,吃用过多容易导致血脂升高、体重增胖。
奶茶粉末:属于反式脂肪酸食物,具有芳香气味,吃用过多容易导致血脂升高、体重增胖。
本发明的优点
本发明的一种高效构建小鼠肥胖模型的高脂饲料中的酪蛋白、L-胱氨酸、纤维素、混合矿物质S10026B、混合维生素V10001C、酒石酸氢胆碱,保证了饲料中能供给小鼠足够的蛋白质、氨基酸、纤维素、矿物质、维生素以及胆碱对维持小鼠正常生长发育具有重要意义。添加人造黄油、花生油、芝麻油、奶茶粉末、葡萄糖,目的是为了提高饲料的致肥胖率和适口性。人造黄油、奶茶粉末属于反式脂肪酸食物,食用过多容易导致肥胖并且黄油和奶茶粉末奶香味较强,能有效提高小鼠的适口性。花生油和芝麻油同时含有丰富的不饱和脂肪酸、胆碱、磷脂、维生素等有益物质,对普通高脂饲料中存在的小鼠皮肤脂质分泌过旺而形成脂溢性脱毛等问题具有良好的改善作用,并且具有芳香气味,也能较好的提高饲料的适口性。葡萄糖的添加是为了让小鼠能直接利用能量并用于身体的供能,有助于能量的过多堆积引起肥胖的发生。使用本发明饲料配方制作而成的60%脂供能高脂饲料,相对于普通60%脂供能高脂饲料实验鼠,毛发较多、并且油性少、毛发油块状少、不容易看到表皮且掉毛少,体型大,体脂多。
附图说明
图1为本发明的小鼠肥胖模型的模型组和对照组的构建方法流程图。
图2为第n周对照组和模型组的小鼠精神状态、毛发油性和脱发程度外观示意图。
具体实施方式
下面结合附图和具体实施例对本发明作进一步的解释和说明,但需要注意的是,本具体实施例不用于限定本发明的权利范围。
材料来源:
协同生物公司60%脂供能高脂饲料(简称XTHF60):江苏省协同医药生物工程有限责任公司的货号为XTHF60。
纤维素为纤维素200FCC,来源于上海聚鹰国际贸易有限公司。
混合矿物质:玉米淀粉(货号:S818265)、一水柠檬酸钾(货号:P816198)、磷酸氢钙(货号:D807979)、碳酸钙(货号:C805317)、氯化钠(货号:S805275)、七水硫酸镁(货号:M813597)、重质氧化镁(货号:M824526)、柠檬酸铁(货号:I809662)、碳酸锰水合物(货号:M813646)等均采购上海麦克林生化科技有限公司
混合维生素:玉米淀粉(货号:S818265)、生育酚乙酸酯(纯度50%)(货号:V820425)、生物素(1%纯度)(货号:B871617)等均采购上海麦克林生化科技有限公司
葡萄糖、人造黄油、麦芽糊精采购北京福润品源商贸有限公司
实施例1:高脂饲料的制作
本实施例1提供的一种高效构建小鼠肥胖模型的高脂饲料为60%脂供能高脂饲料(简称本发明饲料),委托江苏省协同医药生物工程有限责任公司完成制作,该高脂饲料按以下重量百分比的组分组成:23%酪蛋白、0.39%L-胱氨酸、6.46%纤维素、6.46%混合矿物质、0.13%混合维生素、0.26%酒石酸氢胆碱、11%葡萄糖、14.15%麦芽糊精、2.53%花生油、2.53%芝麻油、28%人造黄油、5.09%香芋口味的奶茶粉末。
混合矿物质由以下重量百分比的组分组成:17.985%玉米淀粉、33%一水柠檬酸钾、26%磷酸氢钙、11%碳酸钙、5.18%氯化钠、5.152%七水硫酸镁、0.838%重质氧化镁、0.42%柠檬酸铁、0.245%碳酸锰水合物、0.112%碳酸锌、0.039%硫酸铬钾、0.021%碳酸铜、0.006%氟化钠、0.001%***钠、0.001%碘酸钾。
混合维生素由以下重量百分比的组分组成:78.42%玉米淀粉、10%的纯度为50%的生育酚乙酸酯、3%烟碱、2%的纯度为1%的生物素、1.6%泛酸钙、1%维生素D3(10万IU/g)、1%维生素B12、0.8%维生素醋酸酯(50万IU/g)、0.7%维生素B6盐酸盐、0.6%核黄素、0.6%硫胺素盐酸盐、0.2%叶酸、0.08%水溶性维生素K。
委托江苏省协同医药生物工程有限责任公司制作饲料的方法,包括如下步骤:
(1)按上述重量百分比配制的混合维生素和混合矿物质混合,制成预混料;
(2)将酪蛋白、L-胱氨酸、纤维素、酒石酸氢胆碱、葡萄糖、麦芽糊精、花生油、芝麻油、人造黄油、香芋口味的奶茶粉末分别粉碎,并按上述重量百分比称重配制,一起与步骤(1)的预混料充分搅拌混合;
(3)添加干冰,控制制粒温度进行低温制粒,再采用冷冻干燥机,在温度为28℃的真空环境下干燥8h,制备获得本发明饲料;
(4)将步骤(3)制得的本发明饲料进行包装,并在Co60辐照灭菌。
实施例2
1、提供的一种小鼠肥胖模型的构建方法,包括如下步骤:
(1)购买并挑选30只体重在22.46g±1.2g的6周龄C57BL/6J雄性小鼠,按A1、B、C、A2、D、E分成6组,每组均为5只小鼠,A1、B、C三组为间隔喂养方法,其中,A1为投喂普通生长繁殖饲料的对照组,B为投喂本发明饲料的模型组,C为投喂XTHF60的模型组,A2、D、E为单一喂养方法,其中,A2为投喂普通生长繁殖饲料的对照组,D为投喂本发明饲料的模型组,E为投喂XTHF60的模型组;
(2)步骤(1)的每组小鼠均每天自由摄食和饮水,室温保持在20~22℃,湿度为55%-65%,光照10~15h;
(3)A1组小鼠分别始终投喂普通生长繁殖饲料,直至B组或C组100%成模为止;
B组小鼠分别第1周和第3周分别投喂本发明饲料,第2周和第4周分别投喂普通生长繁殖饲料,第5周至第n周一直投喂本发明饲料直至小鼠肥胖模型成模;
C组小鼠分别第1周和第3周分别投喂XTHF60,第2周和第4周分别投喂普通生长繁殖饲料,第5周至第n周一直投喂XTHF60直至小鼠肥胖模型成模;
A2组小鼠始终投喂普通生长繁殖饲料,直至D组或E组100%成模为止;
D组小鼠每天连续投喂本发明饲料,中途不添加任何其余饲料;
E组小鼠每天连续投喂XTHF60,中途不添加任何其余饲料,喂养至D、E组中任意一组100%成模为止。
A1、A2组为B组阴性对照组;C、D、E组为B组阳性对照组。
如本发明饲料在构建小鼠肥胖模型的应用。
2、判断小鼠肥胖标准
以高出A1或A2对照组小鼠平均体质量的20%作为评判小鼠肥胖模型的成模指标。
3、模型组的小鼠肥胖模型成模率Y%计算方法
Y%表示模型组中每个小鼠在建模过程中比对照组小鼠平均体质量的增重百分比。以超过对照组平均体质量的20%作为肥胖成模指标。
4、检测指标及方法:
(2)每周四22:00将饲料清空用于第二天空腹测血糖,每周五8:00测小鼠血糖;
(3)模型组成模时,检测血清中肝功能:①总胆红素TBIL、直接胆红素DBIL、间接胆红素IBIL。②丙氨酸氨基转移酶ALT、天门冬氨酸氨基转移酶AST;肾功能:尿素Urea、肌酐Cre、尿酸UA。③血脂:总胆固醇TC、甘油三酯TG、低密度脂蛋白LDL、高密度脂蛋白HDL。由桂林市第五人民医院检验科采用全自动生化仪(罗氏Modular P800,USA)测定。
(4)模型组成模时,剪取小鼠肾周脂肪、附睾脂肪、腹股沟脂肪并称重。
(5)观察小鼠精神状态、毛发油性和脱发程度。
5、表1为本发明饲料配方与XTHF60配方的成分、含量、热量的数据对比。
表1:
实施例3实验结果
1.小鼠体重(表2)
第1周末,B组体重增加极其显著(P<0.001),表明本配方适口性较高,能在前期起到快速增重的效果。第6周末,B组与A1组比较,平均体重增长约24.88%(P<0.001),符合小鼠肥胖标准。6周内B组体重平均增长8.4g,但C组仅增长了5g左右,体重增加显著(P<0.01)。D组(本发明饲料+单一喂养方法)的小鼠造模时间需要9周,小鼠体重平均增重10g,且平均体重较A2组平均体重增长约33.86%(P<0.001)。使用本发明饲料配方在两种造模方法上均有优点,首先在确保投喂本发明饲料配方的模型组成模率均达到100%的前提下,D组(单一喂养方法)与B组(间隔喂养方法)比较如下:
(1)单一高脂饲料喂养方法:具有脂体比(脂肪质量/小鼠体质量)高的优点,如D组第8周末成模率可达80%,但仍有20%的小鼠未能达到成模要求,顾会继续喂养直至100%成模,但之前成模的小鼠会继续增胖,脂体比持续增高,得出的肥胖模型效果较显著。
(2)间隔喂养方法:具成模时间同步、成模率高、造模时间短的优点,如第6周末均成模。C组:(XTHF60+间隔喂养方法)在第6周末成模率仅为20%。而E组(XTHF60+单一喂养方法)在第9周末成模率为80%。C组和E组均不能达到快速建立起肥胖模型的效果。而B组(本发明饲料+间隔喂养方法)能快速建立起肥胖模型的效果,大大缩短造模时间。
表2:
B组、C组与A1组比较:*P<0.05,**P<0.01,***P<0.001。
B组与C组比较:#P<0.05,##P<0.01,###P<0.001。
D组、E组与A2组比较:*P<0.05,**P<0.01,***P<0.001。
D组与E组比较:#P<0.05,##P<0.01,###P<0.001。
1.Lee’s指数(表3)
结果表明:B组小鼠初始Lee’s指数与A1组和C组存在差异(P<0.05)。
第1周末,B组与A1、C组两不存在差异、D组相对A2组和E组的Lee’s指数为最高但不存在差异,说明本发明饲料的适口性较高,在经过一周的本发明饲料喂养下,就能快速增高小鼠肥胖指数。第3周末,B组与A1组的Lee’s指数开始出现显著差异(P<0.01)。C组与A1组Lee’s指数在第5周末才开始出现差异(P<0.05),B组与C组在第3周末开始出现差异(P<0.05)。D组在第二周与A2组出现差异,表明本发明饲料通过单一喂养方法能在2周内就升高小鼠肥胖指数且与对照组出现差异,由于B组在第2周投喂的是普通生长繁殖饲料,顾未能出现差异。
综上所述:本发明饲料具有快速增加小鼠肥胖指数的效果,比XTHF60更快速建立起小鼠肥胖模型。B组第6周与D组第9周Lee’s指数不存在差异,进一步的说明了本发明饲料通过间隔喂养方式能更快的增加小鼠肥胖指数。
表3
B组、C组与A1组比较:*P<0.05,**P<0.01,***P<0.001。
B组与C组比较:#P<0.05,##P<0.01,###P<0.001。
D组、E组与A2组比较:*P<0.05,**P<0.01,***P<0.001。
D组与E组比较:#P<0.05,##P<0.01,###P<0.001。
3.血糖变化(表4)
每周四22:00清空饲料仅喂水使小鼠空腹,每周五8:00开始对小鼠进行尾部静脉取血做血糖检测,外部因素和人为操作因素固定不变,但从结果可看出每周小鼠的血糖是不稳定的。但趋势是一定的,如血糖下降则三组小鼠血糖均下降,反之亦然,并且组内差距较小,顾数据是可靠的。
结果表明:第一周末,B组小鼠血糖快速升高,与A1组、C组存在极其显著性差异(P<0.001)进一步验证了本发明饲料在实验第一周对小鼠具有较高适口性,能快速提升小鼠血糖。在第2周末D组比A2组血糖显著性增高(P<0.001),D组小鼠血糖水平始终高于A2组和E组。B组第6周血糖水平与D组第9周血糖水平不存在差异。间隔喂养方法与单一喂养方法相比,在血糖方面无差异,如表4所示。
表4:
B组、C组与A1组比较:*P<0.05,**P<0.01,***P<0.001。
B组与C组比较:#P<0.05,##P<0.01,###P<0.001。
B组、E组与A2组比较:*P<0.05,**P<0.01,***P<0.001。
D组与E组比较:#P<0.05,##P<0.01,###P<0.001。
A2组、D组、E组第2周末血糖数据未检测。
4.小鼠血清生化指标变化(表4)
血清生化检测指标结果显示:模型组肝功能、肾功能不存在药物毒害作用,配方具有实验安全性。但B组、与D组AST指标下降(P<0.05),这与肝组织的代谢能力下降有关,可能会形成脂肪肝,进一步说明本发明饲料配方容易导致肥胖。模型组血脂三项(TC、HDL、LDL)均与对照组存在显著差异。B组与D组TC存在显著差异(P<0.01),这是由于B组造模成功时间一致,而D组存在个别个体成模较快,较快者会继续产生差异,从而加大组间差距。综上所述:本发明饲料配方60%之功能饲料不存在药物毒理性,能放心用于造模。
B组、C组与A1组比较:*P<0.05,**P<0.01,***P<0.001。
B组与C组比较:#P<0.05,##P<0.01,###P<0.001。
D组、E组与A2组比较:*P<0.05,**P<0.01,***P<0.001。
D组与E组比较:#P<0.05,##P<0.01,###P<0.001。
A1组、B组、C组为第6周血清生化指标。A2组、D组、E组为第9周血清生化指标。
5.小鼠肾周脂肪和附睾脂肪、腹股沟脂肪湿重(如表5所示)
结果表明:B组总体脂(Total fat)和内脏脂肪:肾周脂肪+附睾脂肪(Perirenalfat+Epididymal fat)与A1组相比具有显著性差异(P<0.001);B组皮下脂肪:腹股沟脂肪(Abdominal fat)与A1组存在差异(P<0.01);D组总体脂(Total fat)与A2相比具有显著性差异(P<0.01),与E组相比也存在显著差异(P<0.01);内脏脂肪:肾周脂肪+附睾脂肪(Perirenal fat+Epididymal fat)与A2组相比存在显著差异(P<0.01),与E组相比也存在差异(P<0.05);皮下脂肪:腹股沟脂肪(Abdominal fat)与A2组存在差异(P<0.05)。
综上所述:本发明饲料配方比XTHF60配方更容易发生肥胖、能更高效构建小鼠肥胖模型。
表5
B组、C组与A1组比较:*P<0.05,**P<0.01,***P<0.001。
B组与C组比较:#P<0.05,##P<0.01,###P<0.001。
D组、E组与A2组比较:*P<0.05,**P<0.01,***P<0.001。
D组与E组比较:#P<0.05,##P<0.01,###P<0.001。
A1组、B组、C组为第6周脂肪湿重。
A2组、D组、E组为第9周脂肪湿重。
6.第n周造模完成后的小鼠肥胖模型的精神状态、毛发油性和脱发程度如图2所示
(1)精神状态:A1和A2组中的实验鼠,精神状态良好,存在爬鼠笼的现象,活动能力良好。C组和E组中的实验鼠,精神状态萎靡,表现为聚成一块相互取暖,活动能力较低。B组和D组中的实验鼠,精神状态相对C组和E组实验鼠较好,存在爬鼠笼的现象,活动能力一般。
(2)毛发油性和脱发程度:研究显示,饲喂高脂饲料的动物均存在不同程度的脱毛现象,主要是因为小鼠皮肤脂质分泌过旺而形成脂溢性脱毛等问题。结果显示:A1组和A2组小鼠毛发柔顺,光滑有亮度并且不容易脱落。C组和E组鼠,毛发稀疏、油性大、毛发呈油块状、脱发程度严重、能看到表皮并且小鼠严重掉毛。B组和D组:使用本发明饲料配方制作而成的60%脂供能高脂饲料,相对于普通60%脂供能高脂饲料实验鼠,毛发较多、并且油性少、毛发油块状少、不容易看到表皮且掉毛少。从小鼠外观可看出:饲喂本发明饲料的B组和D组体形比其余四组较大,体脂较多。
Claims (8)
1.一种高效构建小鼠肥胖模型的高脂饲料,其特征在于,该高脂饲料由以下组分组成:酪蛋白、L-胱氨酸、纤维素、混合矿物质、混合维生素、酒石酸氢胆碱、葡萄糖、麦芽糊精、花生油、芝麻油、人造黄油、奶茶粉末。
2.根据权利要求1所述的一种高效构建小鼠肥胖模型的高脂饲料,其特征在于,所述高脂饲料由以下重量百分比的组分组成:23%酪蛋白、0.39%L-胱氨酸、6.46%纤维素、6.46%混合矿物质、0.13%混合维生素、0.26%酒石酸氢胆碱、11%葡萄糖、14.15%麦芽糊精、2.53%花生油、2.53%芝麻油、28%人造黄油、5.09%奶茶粉末。
3.根据权利要求1所述的一种高效构建小鼠肥胖模型的高脂饲料,其特征在于,所述奶茶粉末为香芋口味。
4.根据权利要求1所述的一种高效构建小鼠肥胖模型的高脂饲料,其特征在于,所述混合矿物质由以下重量百分比的组分组成:17.985%玉米淀粉、33%一水柠檬酸钾、26%磷酸氢钙、11%碳酸钙、5.18%氯化钠、5.152%七水硫酸镁、0.838%重质氧化镁、0.42%柠檬酸铁、0.245%碳酸锰水合物、0.112%碳酸锌、0.039%硫酸铬钾、0.021%碳酸铜、0.006%氟化钠、0.001%***钠、0.001%碘酸钾。
5.根据权利要求1所述的一种高效构建小鼠肥胖模型的高脂饲料,其特征在于,所述混合维生素由以下重量百分比的组分组成:78.42%玉米淀粉、10%生育酚乙酸酯、3%烟碱、2%生物素、1.6%泛酸钙、1%维生素D3、1%维生素B12、0.8%维生素醋酸酯、0.7%维生素B6盐酸盐、0.6%核黄素、0.6%硫胺素盐酸盐、0.2%叶酸、0.08%水溶性维生素K。
6.根据权利要求1所述的一种高效构建小鼠肥胖模型的高脂饲料,其特征在于,所述生育酚乙酸酯的纯度50%,所述生物素的纯度为1%。
7.如权利要求1所述的一种高效构建小鼠肥胖模型的高脂饲料在构建小鼠肥胖模型的应用。
8.一种小鼠肥胖模型的构建方法,其特征在于,包括如下步骤:小鼠第1周和第3周分别投喂权利要求1所述的高脂饲料,第2周和第4周分别投喂普通生长繁殖饲料,第5周至第n周一直投喂权利要求1所述的高脂饲料直至小鼠肥胖模型成模。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111650332.0A CN114258991A (zh) | 2021-12-30 | 2021-12-30 | 一种高效构建小鼠肥胖模型的高脂饲料及造模方法 |
CN2021116503320 | 2021-12-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114982873A true CN114982873A (zh) | 2022-09-02 |
CN114982873B CN114982873B (zh) | 2023-09-22 |
Family
ID=80831751
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111650332.0A Withdrawn CN114258991A (zh) | 2021-12-30 | 2021-12-30 | 一种高效构建小鼠肥胖模型的高脂饲料及造模方法 |
CN202210363207.XA Active CN114982873B (zh) | 2021-12-30 | 2022-04-07 | 一种高效构建小鼠肥胖模型的高脂饲料及造模方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111650332.0A Withdrawn CN114258991A (zh) | 2021-12-30 | 2021-12-30 | 一种高效构建小鼠肥胖模型的高脂饲料及造模方法 |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN114258991A (zh) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008094797A (ja) * | 2006-10-16 | 2008-04-24 | Morinaga & Co Ltd | 肥満抑制剤及び該肥満抑制剤を含む高脂肪含有飲食品 |
JP2009292811A (ja) * | 2008-05-09 | 2009-12-17 | Fancl Corp | 抗肥満剤 |
US20100189647A1 (en) * | 2006-08-10 | 2010-07-29 | Fusako Takayama | Experimental Animal As Pathological Model, Method of Producing the Experimental Animal, and Method of Using the Experimental Animal |
CN102771673A (zh) * | 2012-08-14 | 2012-11-14 | 江苏美迪森生物医药有限公司 | 一种构建代谢综合症动物模型的高脂纯化饲料及加工工艺 |
CN103782955A (zh) * | 2013-12-25 | 2014-05-14 | 湖南师范大学 | 一种sd大鼠营养性肥胖模型的建立方法 |
CN106234298A (zh) * | 2016-07-22 | 2016-12-21 | 浙江工商大学 | 一种短期内建立高脂血症大鼠模型的方法 |
CN108835444A (zh) * | 2018-07-19 | 2018-11-20 | 李心广 | 种鹅饲料、其制备方法、应用以及禽用食品 |
CN109430156A (zh) * | 2018-09-03 | 2019-03-08 | 浦江县欧立生物技术有限公司 | 胰岛素抵抗动物模型的建立方法 |
CN110558286A (zh) * | 2019-11-05 | 2019-12-13 | 江西中医药大学 | 一种脾虚湿阻型单纯性肥胖动物模型的建立方法 |
-
2021
- 2021-12-30 CN CN202111650332.0A patent/CN114258991A/zh not_active Withdrawn
-
2022
- 2022-04-07 CN CN202210363207.XA patent/CN114982873B/zh active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100189647A1 (en) * | 2006-08-10 | 2010-07-29 | Fusako Takayama | Experimental Animal As Pathological Model, Method of Producing the Experimental Animal, and Method of Using the Experimental Animal |
JP2008094797A (ja) * | 2006-10-16 | 2008-04-24 | Morinaga & Co Ltd | 肥満抑制剤及び該肥満抑制剤を含む高脂肪含有飲食品 |
JP2009292811A (ja) * | 2008-05-09 | 2009-12-17 | Fancl Corp | 抗肥満剤 |
CN102771673A (zh) * | 2012-08-14 | 2012-11-14 | 江苏美迪森生物医药有限公司 | 一种构建代谢综合症动物模型的高脂纯化饲料及加工工艺 |
CN103782955A (zh) * | 2013-12-25 | 2014-05-14 | 湖南师范大学 | 一种sd大鼠营养性肥胖模型的建立方法 |
CN106234298A (zh) * | 2016-07-22 | 2016-12-21 | 浙江工商大学 | 一种短期内建立高脂血症大鼠模型的方法 |
CN108835444A (zh) * | 2018-07-19 | 2018-11-20 | 李心广 | 种鹅饲料、其制备方法、应用以及禽用食品 |
CN109430156A (zh) * | 2018-09-03 | 2019-03-08 | 浦江县欧立生物技术有限公司 | 胰岛素抵抗动物模型的建立方法 |
CN110558286A (zh) * | 2019-11-05 | 2019-12-13 | 江西中医药大学 | 一种脾虚湿阻型单纯性肥胖动物模型的建立方法 |
Non-Patent Citations (5)
Title |
---|
DANIEL ANDERSEN ET AL.: "Systems-wide effects of short-term feed deprivation in obese mice", 《SCI REP》, vol. 11, no. 1, pages 5716 * |
HIRONOBU ET AL.: "Obesity accelerates hair thinning by stem cell-centric converging mechanisms", 《NATURE》, vol. 595, no. 7866, pages 266 - 271, XP037500118, DOI: 10.1038/s41586-021-03624-x * |
李宏睿: "营养性肥胖大鼠模型肠道菌群的微生物多样性分析", 《中国比较医学杂志》, vol. 30, no. 11, pages 335 - 9 * |
楚土等编著, 科学技术文献出版社 * |
田小梅: "混合喂养法诱导营养性肥胖大鼠模型的实验研究", 《实用心脑肺血管病杂志》, vol. 20, no. 3, pages 430 - 432 * |
Also Published As
Publication number | Publication date |
---|---|
CN114982873B (zh) | 2023-09-22 |
CN114258991A (zh) | 2022-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Pugh et al. | Controlling caloric consumption: protocols for rodents and rhesus monkeys☆ | |
Yin et al. | Digestion rate of dietary starch affects the systemic circulation of lipid profiles and lipid metabolism-related gene expression in weaned pigs | |
CN102665704A (zh) | 用于伴侣动物的包含丙酮酸盐的组合物及其使用方法 | |
CN106343217A (zh) | 一种宠物用维生素矿物质营养膏及其制备方法 | |
CN101473900A (zh) | 仔猪断奶全价配合饲料 | |
CN105533696A (zh) | 一种粉剂型肿瘤全营养配方食品 | |
CN106260534A (zh) | 一种狨猴人工配合饲料 | |
CN104642478A (zh) | 一种香菇饼干 | |
CN106538869A (zh) | 一种乳猪饲料 | |
CN104304177A (zh) | 一种富维生素a、富钾鸡蛋的生产方法 | |
Halver | Vitamin requirements | |
CN109845894A (zh) | 一种猫用宠物饼干及加工方法 | |
CN103931947A (zh) | 一种含有Vc的鱼药 | |
CN101756025A (zh) | 水产养殖动物诱食促长内服营养组合物及其制备方法、应用 | |
CN101204199B (zh) | 一种宠物狗饮料添加剂及其制备的狗饮料 | |
CN106243176B (zh) | 蔗糖铜络合物的制备方法 | |
CN114982873A (zh) | 一种高效构建小鼠肥胖模型的高脂饲料及造模方法 | |
CN100360139C (zh) | 排铅助长片及其制备方法 | |
CN102007884A (zh) | 富含多种微量元素鸡蛋的生产方法 | |
CN109892495A (zh) | 一种富硒、锌和铁鸡饲料及富硒、锌和铁鸡蛋的生产方法 | |
CN109984268A (zh) | 一种宠物补钙用维生素营养液及其制备方法 | |
Samman | Trace elements | |
CN106721346A (zh) | 犬猫高吸收蛋白复合物及其制作方法 | |
CN106721498A (zh) | 一种含有Vc的鱼药 | |
CN102972481A (zh) | 一种保健饼干及其制作方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |